SK286169B6 - Použitie konjugovaných estrogénov a medroxyprogesterón acetátu, farmaceutický prostriedok, farmaceutická dávková jednotka a farmaceutický balíček - Google Patents

Použitie konjugovaných estrogénov a medroxyprogesterón acetátu, farmaceutický prostriedok, farmaceutická dávková jednotka a farmaceutický balíček Download PDF

Info

Publication number: SK286169B6
Authority: SK; Slovakia
Prior art keywords: pharmaceutical; conjugated estrogens; daily dosage; medroxyprogesterone acetate; daily
Prior art date: 2000-03-20

Application number

SK1348-2002A

Other languages

English (en)

Slovak (sk)

Other versions

SK13482002A3 (sk

Inventor

James H. Pickar

Original Assignee

Wyeth

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-20

Filing date

2001-03-16

Publication date

2008-04-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26886279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK286169(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-03-16 Application filed by Wyeth filed Critical Wyeth

2003-02-04 Publication of SK13482002A3 publication Critical patent/SK13482002A3/sk

2008-04-07 Publication of SK286169B6 publication Critical patent/SK286169B6/sk

Links

PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 title claims abstract description 101
229960002985 medroxyprogesterone acetate Drugs 0.000 title claims abstract description 97
229940035811 conjugated estrogen Drugs 0.000 title claims abstract description 67
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
238000011282 treatment Methods 0.000 claims abstract description 65
238000004519 manufacturing process Methods 0.000 claims abstract description 16
230000005764 inhibitory process Effects 0.000 claims abstract description 7
229940011871 estrogen Drugs 0.000 claims description 41
239000000262 estrogen Substances 0.000 claims description 41
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
206010060800 Hot flush Diseases 0.000 claims description 15
208000035475 disorder Diseases 0.000 claims description 15
230000002401 inhibitory effect Effects 0.000 claims description 14
230000001457 vasomotor Effects 0.000 claims description 14
208000024891 symptom Diseases 0.000 claims description 13
206010003694 Atrophy Diseases 0.000 claims description 12
208000033830 Hot Flashes Diseases 0.000 claims description 12
230000037444 atrophy Effects 0.000 claims description 12
238000002657 hormone replacement therapy Methods 0.000 claims description 12
206010001928 Amenorrhoea Diseases 0.000 claims description 10
208000001132 Osteoporosis Diseases 0.000 claims description 10
201000000736 Amenorrhea Diseases 0.000 claims description 9
241000283073 Equus caballus Species 0.000 claims description 9
231100000540 amenorrhea Toxicity 0.000 claims description 9
230000000694 effects Effects 0.000 claims description 9
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
208000024827 Alzheimer disease Diseases 0.000 claims description 7
208000018262 Peripheral vascular disease Diseases 0.000 claims description 7
210000000988 bone and bone Anatomy 0.000 claims description 7
206010047791 Vulvovaginal dryness Diseases 0.000 claims description 6
230000032683 aging Effects 0.000 claims description 6
208000024172 Cardiovascular disease Diseases 0.000 claims description 5
230000000740 bleeding effect Effects 0.000 claims description 5
230000018109 developmental process Effects 0.000 claims description 5
238000000034 method Methods 0.000 claims description 5
201000001320 Atherosclerosis Diseases 0.000 claims description 4
208000003251 Pruritus Diseases 0.000 claims description 4
230000037182 bone density Effects 0.000 claims description 4
208000015114 central nervous system disease Diseases 0.000 claims description 4
235000012000 cholesterol Nutrition 0.000 claims description 4
230000006378 damage Effects 0.000 claims description 4
238000005115 demineralization Methods 0.000 claims description 4
230000002328 demineralizing effect Effects 0.000 claims description 4
230000001404 mediated effect Effects 0.000 claims description 4
208000015122 neurodegenerative disease Diseases 0.000 claims description 4
208000004746 Atrophic Vaginitis Diseases 0.000 claims description 3
206010003693 Atrophic vulvovaginitis Diseases 0.000 claims description 3
208000020084 Bone disease Diseases 0.000 claims description 3
206010006298 Breast pain Diseases 0.000 claims description 3
206010012289 Dementia Diseases 0.000 claims description 3
208000031226 Hyperlipidaemia Diseases 0.000 claims description 3
208000006662 Mastodynia Diseases 0.000 claims description 3
206010028980 Neoplasm Diseases 0.000 claims description 3
201000004681 Psoriasis Diseases 0.000 claims description 3
206010046543 Urinary incontinence Diseases 0.000 claims description 3
206010047163 Vasospasm Diseases 0.000 claims description 3
229940038500 a synthetic conjugated estrogen Drugs 0.000 claims description 3
206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
201000011510 cancer Diseases 0.000 claims description 3
210000003169 central nervous system Anatomy 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
206010013990 dysuria Diseases 0.000 claims description 3
230000027939 micturition Effects 0.000 claims description 3
201000010808 postmenopausal atrophic vaginitis Diseases 0.000 claims description 3
230000010410 reperfusion Effects 0.000 claims description 3
201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
208000019206 urinary tract infection Diseases 0.000 claims description 3
230000002792 vascular Effects 0.000 claims description 3
230000003966 vascular damage Effects 0.000 claims description 3
206010008909 Chronic Hepatitis Diseases 0.000 claims description 2
206010014561 Emphysema Diseases 0.000 claims description 2
206010019755 Hepatitis chronic active Diseases 0.000 claims description 2
206010019799 Hepatitis viral Diseases 0.000 claims description 2
208000035150 Hypercholesterolemia Diseases 0.000 claims description 2
206010063837 Reperfusion injury Diseases 0.000 claims description 2
230000009471 action Effects 0.000 claims description 2
230000001363 autoimmune Effects 0.000 claims description 2
230000003920 cognitive function Effects 0.000 claims description 2
230000004054 inflammatory process Effects 0.000 claims description 2
230000003902 lesion Effects 0.000 claims description 2
208000023504 respiratory system disease Diseases 0.000 claims description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
201000008827 tuberculosis Diseases 0.000 claims description 2
230000006441 vascular event Effects 0.000 claims description 2
201000001862 viral hepatitis Diseases 0.000 claims description 2
230000009429 distress Effects 0.000 claims 1
230000004112 neuroprotection Effects 0.000 claims 1
230000000241 respiratory effect Effects 0.000 claims 1
210000002345 respiratory system Anatomy 0.000 claims 1
230000000979 retarding effect Effects 0.000 claims 1
208000011580 syndromic disease Diseases 0.000 claims 1
JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 description 49
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 48
229940063238 premarin Drugs 0.000 description 46
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 42
230000002354 daily effect Effects 0.000 description 29
229960005309 estradiol Drugs 0.000 description 26
229930182833 estradiol Natural products 0.000 description 24
239000000902 placebo Substances 0.000 description 18
229940068196 placebo Drugs 0.000 description 18
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 15
QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 14
239000003826 tablet Substances 0.000 description 14
RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 10
239000000583 progesterone congener Substances 0.000 description 10
238000009164 estrogen replacement therapy Methods 0.000 description 9
230000009245 menopause Effects 0.000 description 9
229910052938 sodium sulfate Inorganic materials 0.000 description 9
235000011152 sodium sulphate Nutrition 0.000 description 9
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 8
201000006828 endometrial hyperplasia Diseases 0.000 description 8
239000000203 mixture Substances 0.000 description 7
108010010234 HDL Lipoproteins Proteins 0.000 description 6
102000015779 HDL Lipoproteins Human genes 0.000 description 6
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 6
108010007622 LDL Lipoproteins Proteins 0.000 description 5
102000007330 LDL Lipoproteins Human genes 0.000 description 5
GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 5
229940062399 cenestin Drugs 0.000 description 5
229960004766 estradiol valerate Drugs 0.000 description 5
150000002632 lipids Chemical class 0.000 description 5
230000009467 reduction Effects 0.000 description 5
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
240000001851 Artemisia dracunculus Species 0.000 description 4
208000004483 Dyspareunia Diseases 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
206010020718 hyperplasia Diseases 0.000 description 4
230000035800 maturation Effects 0.000 description 4
150000003254 radicals Chemical class 0.000 description 4
239000007787 solid Substances 0.000 description 4
GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 3
235000003092 Artemisia dracunculus Nutrition 0.000 description 3
206010065687 Bone loss Diseases 0.000 description 3
206010014733 Endometrial cancer Diseases 0.000 description 3
206010014759 Endometrial neoplasm Diseases 0.000 description 3
WKRLQDKEXYKHJB-UHFFFAOYSA-N Equilin Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3=CCC2=C1 WKRLQDKEXYKHJB-UHFFFAOYSA-N 0.000 description 3
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 3
208000032843 Hemorrhage Diseases 0.000 description 3
206010038687 Respiratory distress Diseases 0.000 description 3
239000003963 antioxidant agent Substances 0.000 description 3
235000006708 antioxidants Nutrition 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
230000008859 change Effects 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
208000029078 coronary artery disease Diseases 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
229960003399 estrone Drugs 0.000 description 3
229950008385 estrone sulphate Drugs 0.000 description 3
HZEQBCVBILBTEP-ZFINNJDLSA-N estropipate Chemical compound C1CNCCN1.OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 HZEQBCVBILBTEP-ZFINNJDLSA-N 0.000 description 3
230000007774 longterm Effects 0.000 description 3
210000004705 lumbosacral region Anatomy 0.000 description 3
239000011777 magnesium Substances 0.000 description 3
229960001566 methyltestosterone Drugs 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000011269 treatment regimen Methods 0.000 description 3
229940044959 vaginal cream Drugs 0.000 description 3
239000000522 vaginal cream Substances 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
VOXZDWNPVJITMN-SFFUCWETSA-N 17α-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-SFFUCWETSA-N 0.000 description 2
206010067484 Adverse reaction Diseases 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
108010023302 HDL Cholesterol Proteins 0.000 description 2
108010028554 LDL Cholesterol Proteins 0.000 description 2
208000017657 Menopausal disease Diseases 0.000 description 2
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
206010046788 Uterine haemorrhage Diseases 0.000 description 2
206010046910 Vaginal haemorrhage Diseases 0.000 description 2
MPSOHXLZDRQABN-KOAPPJMKSA-N [(8r,9s,10r,13s,14s,17r)-17-ethynyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol;(8r,9s,13s,14s,16r,17 Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1.C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 MPSOHXLZDRQABN-KOAPPJMKSA-N 0.000 description 2
230000002411 adverse Effects 0.000 description 2
230000006838 adverse reaction Effects 0.000 description 2
239000000969 carrier Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
229940108922 climara Drugs 0.000 description 2
239000007891 compressed tablet Substances 0.000 description 2
230000001054 cortical effect Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
NFDFQCUYFHCNBW-SCGPFSFSSA-N dienestrol Chemical compound C=1C=C(O)C=CC=1\C(=C/C)\C(=C\C)\C1=CC=C(O)C=C1 NFDFQCUYFHCNBW-SCGPFSFSSA-N 0.000 description 2
229960003839 dienestrol Drugs 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 description 2
229960004913 dydrogesterone Drugs 0.000 description 2
230000002357 endometrial effect Effects 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
PDRGHUMCVRDZLQ-WMZOPIPTSA-N equilenin Chemical compound OC1=CC=C2C(CC[C@]3([C@H]4CCC3=O)C)=C4C=CC2=C1 PDRGHUMCVRDZLQ-WMZOPIPTSA-N 0.000 description 2
229940064258 estrace Drugs 0.000 description 2
229940074117 estraderm Drugs 0.000 description 2
PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 2
230000001076 estrogenic effect Effects 0.000 description 2
VUCAHVBMSFIGAI-ZFINNJDLSA-M estrone sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 VUCAHVBMSFIGAI-ZFINNJDLSA-M 0.000 description 2
229940081345 estropipate Drugs 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
230000006870 function Effects 0.000 description 2
239000008187 granular material Substances 0.000 description 2
208000006454 hepatitis Diseases 0.000 description 2
231100000283 hepatitis Toxicity 0.000 description 2
210000001624 hip Anatomy 0.000 description 2
230000006872 improvement Effects 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
206010022437 insomnia Diseases 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000005906 menstruation Effects 0.000 description 2
239000011707 mineral Substances 0.000 description 2
208000031225 myocardial ischemia Diseases 0.000 description 2
230000000324 neuroprotective effect Effects 0.000 description 2
230000002611 ovarian Effects 0.000 description 2
230000008092 positive effect Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000002265 prevention Effects 0.000 description 2
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008107 starch Substances 0.000 description 2
230000003637 steroidlike Effects 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
229910021653 sulphate ion Inorganic materials 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
210000000689 upper leg Anatomy 0.000 description 2
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
WFHDOIKSUKQTLH-IBXXTFBESA-N (8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one;[(8r,9s,13s,14s,17s)-3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] pentanoate Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 WFHDOIKSUKQTLH-IBXXTFBESA-N 0.000 description 1
RVXHNBHNODFRPZ-JBOOOYMWSA-N (8r,9s,10r,13s,14s,17r)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RVXHNBHNODFRPZ-JBOOOYMWSA-N 0.000 description 1
229930182834 17alpha-Estradiol Natural products 0.000 description 1
BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
239000004255 Butylated hydroxyanisole Substances 0.000 description 1
239000004322 Butylated hydroxytoluene Substances 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
206010014486 Elevated triglycerides Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010027339 Menstruation irregular Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
208000001738 Nervous System Trauma Diseases 0.000 description 1
206010029216 Nervousness Diseases 0.000 description 1
IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
241000209140 Triticum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
OZPWNCNLFBVVEN-RFYLDXRNSA-N [(6s,8r,9s,10r,13s,14s,17r)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate;[(9s,13s,14s)-13-methyl-17-oxo-9,11,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate;[(8r,9 Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1.OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1.OS(=O)(=O)OC1=CC=C2C(CC[C@]3([C@H]4CCC3=O)C)=C4C=CC2=C1.C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 OZPWNCNLFBVVEN-RFYLDXRNSA-N 0.000 description 1
NAUDKYVGHCCLOT-LAQCMFAESA-N [(8r,9s,10r,13s,14s,17r)-17-ethynyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 NAUDKYVGHCCLOT-LAQCMFAESA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
229940060585 alora Drugs 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
150000001441 androstanes Chemical class 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
230000037007 arousal Effects 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000003293 cardioprotective effect Effects 0.000 description 1
230000011748 cell maturation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000004040 coloring Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
PDRGHUMCVRDZLQ-UHFFFAOYSA-N d-equilenin Natural products OC1=CC=C2C(CCC3(C4CCC3=O)C)=C4C=CC2=C1 PDRGHUMCVRDZLQ-UHFFFAOYSA-N 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
230000004821 effect on bone Effects 0.000 description 1
229940098618 estring Drugs 0.000 description 1
229960001348 estriol Drugs 0.000 description 1
229940106582 estrogenic substances Drugs 0.000 description 1
229960002568 ethinylestradiol Drugs 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
229940085363 evista Drugs 0.000 description 1
229940006346 femhrt Drugs 0.000 description 1
210000002436 femur neck Anatomy 0.000 description 1
238000009501 film coating Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229930182480 glucuronide Natural products 0.000 description 1
150000008134 glucuronides Chemical class 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
229960001021 lactose monohydrate Drugs 0.000 description 1
229960004400 levonorgestrel Drugs 0.000 description 1
229940080398 levonorgestrel 0.25 mg Drugs 0.000 description 1
UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229960004616 medroxyprogesterone Drugs 0.000 description 1
230000003821 menstrual periods Effects 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
206010063344 microscopic polyangiitis Diseases 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
229960001652 norethindrone acetate Drugs 0.000 description 1
235000019488 nut oil Nutrition 0.000 description 1
239000010466 nut oil Substances 0.000 description 1
230000027758 ovulation cycle Effects 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
210000004197 pelvis Anatomy 0.000 description 1
230000002688 persistence Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
235000002378 plant sterols Nutrition 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
JWMFYGXQPXQEEM-WZBAXQLOSA-N pregnane Chemical class C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](CC)[C@@]1(C)CC2 JWMFYGXQPXQEEM-WZBAXQLOSA-N 0.000 description 1
230000002028 premature Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
229960004622 raloxifene Drugs 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
229940095743 selective estrogen receptor modulator Drugs 0.000 description 1
239000000333 selective estrogen receptor modulator Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
208000023516 stroke disease Diseases 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
238000009495 sugar coating Methods 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
239000002700 tablet coating Substances 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000001069 triethyl citrate Substances 0.000 description 1
235000013769 triethyl citrate Nutrition 0.000 description 1
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
229940053743 vivelle Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
-1 wheat Chemical compound 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Reproductive Health (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)

SK1348-2002A 2000-03-20 2001-03-16 Použitie konjugovaných estrogénov a medroxyprogesterón acetátu, farmaceutický prostriedok, farmaceutická dávková jednotka a farmaceutický balíček SK286169B6 (sk)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US19063000P	2000-03-20	2000-03-20
US26860701P	2001-02-14	2001-02-14
PCT/US2001/040302 WO2001070208A2 (en)	2000-03-20	2001-03-16	Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate

Publications (2)

Publication Number	Publication Date
SK13482002A3 SK13482002A3 (sk)	2003-02-04
SK286169B6 true SK286169B6 (sk)	2008-04-07

Family

ID=26886279

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1348-2002A SK286169B6 (sk)	2000-03-20	2001-03-16	Použitie konjugovaných estrogénov a medroxyprogesterón acetátu, farmaceutický prostriedok, farmaceutická dávková jednotka a farmaceutický balíček

Country Status (30)

Country	Link
US (2)	US20010034340A1 (pl)
EP (1)	EP1265616B1 (pl)
JP (1)	JP2003527416A (pl)
KR (1)	KR100805648B1 (pl)
CN (1)	CN1239160C (pl)
AR (1)	AR031563A1 (pl)
AT (1)	ATE326227T1 (pl)
AU (2)	AU2001250034B2 (pl)
BG (1)	BG66075B1 (pl)
BR (1)	BR0109334A (pl)
CA (1)	CA2402983A1 (pl)
CY (1)	CY1105632T1 (pl)
CZ (1)	CZ20023162A3 (pl)
DE (1)	DE60119703T2 (pl)
DK (1)	DK1265616T3 (pl)
EA (1)	EA005592B1 (pl)
EE (1)	EE05129B1 (pl)
ES (1)	ES2261393T3 (pl)
HK (1)	HK1049449B (pl)
HR (1)	HRP20020837B1 (pl)
HU (1)	HUP0302093A3 (pl)
IL (1)	IL151512A0 (pl)
MX (1)	MXPA02009116A (pl)
NO (1)	NO326886B1 (pl)
NZ (1)	NZ521171A (pl)
PL (1)	PL201762B1 (pl)
PT (1)	PT1265616E (pl)
SK (1)	SK286169B6 (pl)
TW (1)	TWI271194B (pl)
WO (1)	WO2001070208A2 (pl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20010044431A1 (en) *	2000-03-21	2001-11-22	Rodriguez Gustavo C.	Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US6245819B1 (en) *	2000-07-21	2001-06-12	Hormos Medical Oy, Ltd.	Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
MXPA03008367A (es) *	2001-03-16	2004-11-12	Wyeth Corp	Terapia de reemplazamiento de hormonas.
EP1857110A3 (en) *	2001-03-16	2008-08-06	Wyeth	Hormone replacement therapy
WO2008150547A1 (en)	2007-06-04	2008-12-11	The Regents Of The University Of California	Pregnancy hormone combination for treatment of autoimmune diseases
US20130203722A1 (en)	2006-09-26	2013-08-08	Rhonda R. Voskuhl	Estriol therapy for autoimmune and neurodegenerative disease and disorders
TWI252111B (en) *	2001-12-14	2006-04-01	Solvay Pharm Gmbh	Matrix film tablet with controlled release of a natural mixture of conjugated estrogens
TW200306196A (en) *	2002-04-03	2003-11-16	Wyeth Corp	Hormone replacement therapy
TW200306846A (en) *	2002-04-03	2003-12-01	Wyeth Corp	Hormone replacement therapy
EP1494679A4 (en) *	2002-04-03	2009-10-28	Barr Lab Inc	STEP-BY-STEP ESTROGENTHERAPY
TW200306851A (en) *	2002-04-29	2003-12-01	Wyeth Corp	Hormone replacement therapy
TW200400040A (en) *	2002-05-17	2004-01-01	Wyeth Corp	Hormone replacement therapy
MXPA04012220A (es) *	2002-06-06	2005-04-08	Hormos Medical Corp	Metodo para la inhibicion de la atrofia o para el tratamiento o la prevencion de los sintomas relacionados con la atrofia en mujeres.
RU2005101638A (ru) *	2002-06-25	2006-01-20	Уайт (Us)	Использование циклокарбаматных производных для лечения гормонзависимых состояний
RU2005101635A (ru) *	2002-06-25	2005-08-10	Уайт (Us)	Применение производных тиооксиндола в терапии гормонозависимых состояний
US8349819B2 (en)	2002-10-09	2013-01-08	Dr. Reddy's Laboratories New York, Inc.	Steroid extraction process from urine sources
MXPA05010871A (es) *	2003-04-11	2005-11-25	Barr Lab Inc	Metodos para administrar estrogenos y progestinas.
US20060040904A1 (en) *	2004-08-17	2006-02-23	Ahmed Salah U	Vaginal cream compositions, kits thereof and methods of using thereof
WO2007076144A2 (en)	2005-12-27	2007-07-05	Duramed Pharmaceuticals, Inc.	Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
MX2008012880A (es) *	2006-04-05	2008-10-13	Wyeth Corp	Metodos para la prevencion y tratamiento de condiciones que surgen de deficiencia de estrogeno local.
TW200831139A (en) *	2006-11-29	2008-08-01	Wyeth Corp	Estrogen/SERM and estrogen/progestin bi-layer tablets
PL2121553T3 (pl) *	2007-02-14	2012-11-30	Hormos Medical Ltd	Sposób wytwarzania cennych terapeutycznie pochodnych trifenylobutenu
WO2008099060A2 (en) *	2007-02-14	2008-08-21	Hormos Medical Ltd	Methods for the preparation of fispemifene from ospemifene
KR100989093B1 (ko)	2008-01-18	2010-10-25	한화제약주식회사	생강나무 가지의 추출물을 포함하는 심혈관계 질환의 예방 및 치료용 조성물
US9734496B2 (en)	2009-05-29	2017-08-15	Paypal, Inc.	Trusted remote attestation agent (TRAA)
ES2773079T3 (es) *	2010-02-08	2020-07-09	Shenzhen Evergreen Therapeutics Co Ltd	Métodos para el uso de progestágeno como sensibilizador de glucocorticoides
US8633178B2 (en)	2011-11-23	2014-01-21	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9321712B2 (en)	2012-10-19	2016-04-26	Fermion Oy	Process for the preparation of ospemifene
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
US11224603B2 (en) *	2013-12-13	2022-01-18	Requis Pharmaceuticals, Inc.	Antihistamines in combination with a range of substances for improved health
US10799512B2 (en)	2014-04-28	2020-10-13	The Regents Of The University Of California	Estrogen combination for treatment of multiple sclerosis
WO2015168002A1 (en)	2014-04-28	2015-11-05	The Regents Of The University Of California	Pharmaceutical packaging for estriol therapy
EP3145489A1 (en)	2014-05-22	2017-03-29	TherapeuticsMD, Inc.	Natural combination hormone replacement formulations and therapies
EP3188735A4 (en)	2014-09-02	2018-01-24	The Regents of the University of California	Estrogen therapy for brain gray matter atrophy and associated disability
ES2957543T3 (es) *	2014-09-29	2024-01-22	Univ California	Composiciones y métodos para mantener la función cognitiva
WO2016160832A1 (en)	2015-03-30	2016-10-06	The Regents Of The University Of California	Methods of monitoring estriol therapy
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
WO2017173044A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd Inc.	Steroid hormone compositions in medium chain oils
WO2017173071A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical composition
WO2020081726A1 (en) *	2018-10-17	2020-04-23	Stadler Sarah Sheehan	Methods of treating menopausal symptoms using low dose progesterone
US11633405B2 (en)	2020-02-07	2023-04-25	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU582540B2 (en) *	1983-08-05	1989-04-06	Pre Jay Holdings Ltd.	A method of hormonal treatment of perimenopausal, menopausal and post-menopausal disorders and multi-preparation pack therefor
US4826831A (en) *	1983-08-05	1989-05-02	Pre Jay Holdings Limited	Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
DE3888269T2 (de) *	1987-09-24	1994-07-07	Jencap Research Ltd	Hormon-Zusammensetzung und -Anwendung.
NL9301562A (nl) *	1993-09-09	1995-04-03	Saturnus Ag	Preparaat voor substitutietherapie.
US5554601A (en) *	1993-11-05	1996-09-10	University Of Florida	Methods for neuroprotection
US5547948A (en) *	1995-01-17	1996-08-20	American Home Products Corporation	Controlled release of steroids from sugar coatings
US5759577A (en) *	1995-01-17	1998-06-02	American Home Products Corporation	Controlled release of steroids from sugar coatings

2001
- 2001-03-15 US US09/808,878 patent/US20010034340A1/en not_active Abandoned
- 2001-03-16 EP EP01923331A patent/EP1265616B1/en not_active Expired - Lifetime
- 2001-03-16 AU AU2001250034A patent/AU2001250034B2/en not_active Ceased
- 2001-03-16 HK HK03101651.5A patent/HK1049449B/en not_active IP Right Cessation
- 2001-03-16 SK SK1348-2002A patent/SK286169B6/sk not_active IP Right Cessation
- 2001-03-16 ES ES01923331T patent/ES2261393T3/es not_active Expired - Lifetime
- 2001-03-16 BR BR0109334-7A patent/BR0109334A/pt not_active Application Discontinuation
- 2001-03-16 HR HR20020837A patent/HRP20020837B1/xx not_active IP Right Cessation
- 2001-03-16 DK DK01923331T patent/DK1265616T3/da active
- 2001-03-16 CZ CZ20023162A patent/CZ20023162A3/cs unknown
- 2001-03-16 PT PT01923331T patent/PT1265616E/pt unknown
- 2001-03-16 EA EA200201000A patent/EA005592B1/ru not_active IP Right Cessation
- 2001-03-16 EE EEP200200535A patent/EE05129B1/xx not_active IP Right Cessation
- 2001-03-16 WO PCT/US2001/040302 patent/WO2001070208A2/en not_active Ceased
- 2001-03-16 AT AT01923331T patent/ATE326227T1/de active
- 2001-03-16 HU HU0302093A patent/HUP0302093A3/hu unknown
- 2001-03-16 CN CNB018068235A patent/CN1239160C/zh not_active Expired - Fee Related
- 2001-03-16 IL IL15151201A patent/IL151512A0/xx not_active IP Right Cessation
- 2001-03-16 JP JP2001568406A patent/JP2003527416A/ja active Pending
- 2001-03-16 KR KR1020027012420A patent/KR100805648B1/ko not_active Expired - Fee Related
- 2001-03-16 DE DE60119703T patent/DE60119703T2/de not_active Expired - Lifetime
- 2001-03-16 MX MXPA02009116A patent/MXPA02009116A/es active IP Right Grant
- 2001-03-16 PL PL363157A patent/PL201762B1/pl not_active IP Right Cessation
- 2001-03-16 CA CA002402983A patent/CA2402983A1/en not_active Abandoned
- 2001-03-16 AU AU5003401A patent/AU5003401A/xx active Pending
- 2001-03-16 NZ NZ521171A patent/NZ521171A/en not_active IP Right Cessation
- 2001-03-19 AR ARP010101273A patent/AR031563A1/es unknown
- 2001-03-19 TW TW090106349A patent/TWI271194B/zh not_active IP Right Cessation
2002
- 2002-09-12 BG BG107095A patent/BG66075B1/xx unknown
- 2002-09-19 NO NO20024478A patent/NO326886B1/no not_active IP Right Cessation
2006
- 2006-07-03 CY CY20061100910T patent/CY1105632T1/el unknown
2007
- 2007-11-06 US US11/979,633 patent/US20090005351A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NO326886B1 (no)	2009-03-16
WO2001070208A2 (en)	2001-09-27
US20090005351A1 (en)	2009-01-01
SK13482002A3 (sk)	2003-02-04
DE60119703T2 (de)	2006-10-19
BR0109334A (pt)	2002-12-24
PL363157A1 (pl)	2004-11-15
JP2003527416A (ja)	2003-09-16
HRP20020837A2 (en)	2004-02-29
EA005592B1 (ru)	2005-04-28
EP1265616A2 (en)	2002-12-18
EP1265616B1 (en)	2006-05-17
EA200201000A1 (ru)	2003-02-27
TWI271194B (en)	2007-01-21
ATE326227T1 (de)	2006-06-15
AR031563A1 (es)	2003-09-24
BG66075B1 (en)	2011-02-28
NO20024478L (no)	2002-09-19
NO20024478D0 (no)	2002-09-19
HK1049449A1 (en)	2003-05-16
NZ521171A (en)	2004-09-24
CN1418102A (zh)	2003-05-14
CA2402983A1 (en)	2001-09-27
DE60119703D1 (de)	2006-06-22
PL201762B1 (pl)	2009-05-29
WO2001070208A3 (en)	2002-04-25
HK1049449B (en)	2006-07-28
DK1265616T3 (da)	2006-06-12
BG107095A (bg)	2003-05-30
EE200200535A (et)	2004-04-15
EE05129B1 (et)	2009-02-16
HUP0302093A2 (hu)	2003-10-28
KR100805648B1 (ko)	2008-02-26
CN1239160C (zh)	2006-02-01
HUP0302093A3 (en)	2010-03-29
CZ20023162A3 (cs)	2003-03-12
AU5003401A (en)	2001-10-03
ES2261393T3 (es)	2006-11-16
PT1265616E (pt)	2006-08-31
AU2001250034B2 (en)	2005-03-24
IL151512A0 (en)	2003-04-10
CY1105632T1 (el)	2010-12-22
KR20020084230A (ko)	2002-11-04
US20010034340A1 (en)	2001-10-25
MXPA02009116A (es)	2003-03-12
HRP20020837B1 (hr)	2007-08-31

Legal Events

Date	Code	Title	Description
2012-12-03	MM4A	Patent lapsed due to non-payment of maintenance fees	Effective date: 20120316

Publication	Publication Date	Title
SK286169B6 (sk)	2008-04-07	Použitie konjugovaných estrogénov a medroxyprogesterón acetátu, farmaceutický prostriedok, farmaceutická dávková jednotka a farmaceutický balíček
AU2001250034A1 (en)	2001-12-13	Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate
US20020169150A1 (en)	2002-11-14	Hormone replacement therapy
AU2002336245A1 (en)	2003-03-27	Hormone replacement therapy
US20030216367A1 (en)	2003-11-20	Hormone replacement therapy
AU2003234574A1 (en)	2003-12-02	Trimegestone and estrogens for treating post menopausal disorders
US20030191103A1 (en)	2003-10-09	Hormone replacement therapy
US20030191097A1 (en)	2003-10-09	Hormone replacement therapy
US20030207850A1 (en)	2003-11-06	Hormone replacement therapy
ZA200208369B (en)	2004-01-26	Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate.